ZTS
A decent quarter, not a barn-burning one
Zoetis opened 2026 with a pretty respectable first quarter, reporting $2.3 billion in revenue, up 3% from a year ago. Strip out the noise and organic operational growth was flat, which is the kind of result that says, “steady hands on the wheel,” not “melt-your-face-off acceleration.”
Net income came in at $601 million, and diluted EPS landed at $1.42, up 6%. That’s the part investors tend to care about most: the business is still converting sales into earnings, even if top-line growth isn’t exactly galloping.
Why you should care
Zoetis is basically the veterinarian’s version of a consumer staples company — pets, livestock, recurring demand, and not a ton of drama. So when it posts a quarter like this, the market usually reads it as a check on whether the animal-health engine is still humming.
- Revenue: $2.3 billion, +3%
- Organic operational growth: flat
- Net income: $601 million
- Diluted EPS: $1.42, +6%
The big picture
This isn’t a blockbuster “to the moon” quarter, but it does show Zoetis keeping growth in the lane while still expanding earnings. In a market that loves stability almost as much as it loves a good breakout, that can still matter.
Big picture: sometimes the best thing a healthcare-adjacent company can do is look boring in exactly the right way.